144 related articles for article (PubMed ID: 37661222)
1. Association of Moderate-Risk Breast Cancer Genes with Contralateral Prophylactic Mastectomy and Bilateral Disease.
Zhang JQ; Dos Anjos CH; Sevilimedu V; Crown A; Amoroso KA; Pilewskie ML; Robson ME; Gemignani ML
Ann Surg Oncol; 2023 Nov; 30(12):6990-6999. PubMed ID: 37661222
[TBL] [Abstract][Full Text] [Related]
2. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
[TBL] [Abstract][Full Text] [Related]
3. Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.
Ro V; McGuinness JE; Guo B; Trivedi MS; Jones T; Chung WK; Rao R; Levinson E; Koval C; Russo D; Chilton I; Kukafka R; Crew KD
JCO Oncol Pract; 2022 Apr; 18(4):e472-e483. PubMed ID: 34705516
[TBL] [Abstract][Full Text] [Related]
4. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
[TBL] [Abstract][Full Text] [Related]
5. Influence of germline test results on surgical decision making in women with invasive breast cancer.
Vargason AB; Turner CE; Shriver CD; Ellsworth RE
Cancer Genet; 2022 Aug; 266-267():81-85. PubMed ID: 35868102
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
7. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
[TBL] [Abstract][Full Text] [Related]
8. Trends in Contralateral Prophylactic Mastectomy.
Fairbairn K; Cervantes A; Rayhrer C; Steen S
Aesthetic Plast Surg; 2020 Apr; 44(2):323-329. PubMed ID: 31853610
[TBL] [Abstract][Full Text] [Related]
9. Contralateral Prophylactic Mastectomy in Patients with Breast Cancer.
Noditi A; Caragheorghe G; Stoleru S; Blidaru A; Bordea CI
Chirurgia (Bucur); 2021; 116(2 Suppl):73-83. PubMed ID: 33963696
[No Abstract] [Full Text] [Related]
10. Contralateral prophylactic mastectomy in an Asian population: a single institution review.
Sim Y; Tan VK; Ho GH; Wong CY; Madhukumar P; Tan BK; Yong WS; Ng YY; Ong KW
Breast; 2014 Feb; 23(1):56-62. PubMed ID: 24275318
[TBL] [Abstract][Full Text] [Related]
11. Breast reconstruction in patients with personal and family history of breast cancer undergoing contralateral prophylactic mastectomy, a 10-year experience.
Unukovych D; Sandelin K; Wickman M; Arver B; Johansson H; Brandberg Y; Liljegren A
Acta Oncol; 2012 Sep; 51(7):934-41. PubMed ID: 22409595
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.
Fencer MG; Krupa KA; Bleich GC; Grumet S; Eladoumikdachi FG; Kumar S; Kowzun MJ; Potdevin LB
Clin Breast Cancer; 2023 Jun; 23(4):e194-e199. PubMed ID: 36966080
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
Hamilton JG; Genoff MC; Salerno M; Amoroso K; Boyar SR; Sheehan M; Fleischut MH; Siegel B; Arnold AG; Salo-Mullen EE; Hay JL; Offit K; Robson ME
Breast Cancer Res Treat; 2017 Apr; 162(2):297-306. PubMed ID: 28150129
[TBL] [Abstract][Full Text] [Related]
14. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
Tynan M; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill SC; Jandorf L; Kelly SP; Heinzmann J; Kelleher S; Poggi E; Schwartz MD
Breast Cancer Res Treat; 2020 Feb; 180(1):177-185. PubMed ID: 31894446
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.
Hegde JV; Wang X; Attai DJ; DiNome ML; Kusske A; Hoyt AC; Hurvitz SA; Weidhaas JB; Steinberg ML; McCloskey SA
Clin Breast Cancer; 2018 Apr; 18(2):e205-e218. PubMed ID: 29050918
[TBL] [Abstract][Full Text] [Related]
16. Indications for Contralateral Prophylactic Mastectomy: A Consensus Statement Using Modified Delphi Methodology.
Wright FC; Look Hong NJ; Quan ML; Beyfuss K; Temple S; Covelli A; Baxter N; Gagliardi AR
Ann Surg; 2018 Feb; 267(2):271-279. PubMed ID: 28594745
[TBL] [Abstract][Full Text] [Related]
17. Trends of Contralateral prophylactic mastectomy at the time of ipsilateral breast tumor recurrence.
ElSherif A; Armanyous S; Gentle CK; Al-Hilli Z; Valente SA
Am J Surg; 2022 Mar; 223(3):533-537. PubMed ID: 34924172
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic mastectomy for the prevention of breast cancer.
Lostumbo L; Carbine N; Wallace J; Ezzo J
Cochrane Database Syst Rev; 2004 Oct; (4):CD002748. PubMed ID: 15495033
[TBL] [Abstract][Full Text] [Related]
19. B-Sure: a randomized pilot trial of an interactive web-based decision support aid versus usual care in average-risk breast cancer patients considering contralateral prophylactic mastectomy.
Manne SL; Smith BL; Frederick S; Mitarotondo A; Kashy DA; Kirstein LJ
Transl Behav Med; 2020 May; 10(2):355-363. PubMed ID: 30608607
[TBL] [Abstract][Full Text] [Related]
20. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
